Impact of Ixekizumab on Work Productivity in Patients with Ankylosing Spondylitis: Results from the COAST-V and COAST-W Trials at 52 Weeks

INTRODUCTION: Patients with ankylosing spondylitis (AS) are burdened with symptoms impacting work productivity measured by presenteeism, absenteeism, overall work impairment, and activity impairment. Ixekizumab, a high-affinity monoclonal antibody selectively targeting interleukin-17A, has been demo...

Descripción completa

Detalles Bibliográficos
Autores principales: Marzo-Ortega, Helena, Mease, Philip J., Rahman, Proton, Navarro-Compán, Victoria, Strand, Vibeke, Dougados, Maxime, Combe, Bernard, Wei, James Cheng-Chung, Baraliakos, Xenofon, Hunter, Theresa, Sandoval, David, Li, Xiaoqi, Zhu, Baojin, Bessette, Louis, Deodhar, Atul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695773/
https://www.ncbi.nlm.nih.gov/pubmed/32814997
http://dx.doi.org/10.1007/s40744-020-00225-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695773/
https://www.ncbi.nlm.nih.gov/pubmed/32814997
http://dx.doi.org/10.1007/s40744-020-00225-4

Ejemplares similares